Prime Medicine (PRME) Gains from Investment Securities (2022 - 2025)
Prime Medicine posted quarterly Gains from Investment Securities of -$83.3 million for Q4 2025, down 138975.0% year-on-year from N/an in Q4 2024, and down 197.66% on a QoQ basis from $85.3 million in Q3 2025.
Prime Medicine (PRME) has 4 years of Gains from Investment Securities data on file, last reported at -$83.3 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 138975.0% year-over-year to -$83.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 million (up 103.2% YoY), and the FY2025 full-year result was $432000.0, up 189.26% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at -$83.3 million, down from $85.3 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $85.3 million in Q3 2025 and bottomed at -$83.3 million in Q4 2025.
- The 4-year median for Gains from Investment Securities is -$244000.0 (2022), against an average of -$586285.7.
- The widest annual swing landed in 2024, when Gains from Investment Securities soared 2741.68%; it then tumbled 138975.0% in 2025.
- A 4-year view of Gains from Investment Securities shows it stood at -$36.7 million in 2022, then jumped by 108.14% to $3.0 million in 2023, then sank by 97.99% to $60000.0 in 2024, then sank by 138975.0% to -$83.3 million in 2025.
- The last three Gains from Investment Securities figures came in at -$83.3 million (Q4 2025), $85.3 million (Q3 2025), and -$505000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Prime Medicine | 601.24 Mn | 601.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -83.33 Mn |
| Dec 31, 2025 | -83.33 Mn |
| Sep 30, 2025 | 85.32 Mn |
| Sep 30, 2025 | 85.32 Mn |
| Jun 30, 2025 | -505,000.00 |
| Jun 30, 2025 | -505,000.00 |
| Mar 31, 2025 | -1.06 Mn |
| Mar 31, 2025 | -1.06 Mn |
| Dec 31, 2024 | 60,000.00 |
| Dec 31, 2024 | 60,000.00 |
| Sep 30, 2024 | -45.48 Mn |
| Sep 30, 2024 | -45.48 Mn |
| Mar 31, 2024 | 44.94 Mn |
| Mar 31, 2024 | 44.94 Mn |
| Dec 31, 2023 | 2.99 Mn |
| Dec 31, 2023 | 2.99 Mn |
| Sep 30, 2023 | -6.28 Mn |
| Sep 30, 2023 | -6.28 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Jun 30, 2023 | 4.97 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Mar 31, 2023 | -1.70 Mn |
| Dec 31, 2022 | -36.72 Mn |
| Dec 31, 2022 | -36.72 Mn |
| Sep 30, 2022 | 17,000.00 |
| Sep 30, 2022 | 17,000.00 |
| Jun 30, 2022 | 28.57 Mn |
| Jun 30, 2022 | 28.57 Mn |